Repositioning of Anti-parasitic Drugs in Cyclodextrin Inclusion Complexes for Treatment of Triple-Negative Breast Cancer

PRIOTTI, JOSEFINA; RICO, MARÍA JOSÉ; MENACHO MÁRQUEZ, MAURICIO; GARCÍA, AGUSTINA; LAMAS, MARÍA CELINA; BAGLIONI, MARÍA VIRGINIA; LEONARDI, DARÍO; PRIOTTI, JOSEFINA; RICO, MARÍA JOSÉ; MENACHO MÁRQUEZ, MAURICIO; GARCÍA, AGUSTINA; LAMAS, MARÍA CELINA; BAGLIONI, MARÍA VIRGINIA; LEONARDI, DARÍO

AAPS PHARMSCITECH

SPRINGER

Lugar: Arlington; Año: 2018 vol. 19 p. 3734 - 3741

1530-9932

Drug repositioning refers to the identification of new therapeutic indications fordrugs already approved. Albendazole and ricobendazole have been used as anti-parasiticdrugs for many years; their therapeutic action is based on the inhibition of microtubuleformation. Therefore, the study of their properties as antitumor compounds and the design ofan appropriate formulation for cancer therapy is an interesting issue to investigate. Theselected compounds are poorly soluble in water, and consequently, they have low and erraticbioavailability. In order to improve their biopharmaceutics properties, several formulationsemploying cyclodextrin inclusion complexes were developed. To carefully evaluate thein vitro and in vivo antitumor activity of these drugs and their complexes, several studies wereperformed on a breast cancer cell line (4T1) and BALB/c mice. In vitro studies showed thatalbendazole presented improved antitumor activity compared with ricobendazole. Furthermore,albendazole:citrate-β-cyclodextrin complex decreased significantly 4T1 cell growthboth in in vitro and in vivo experiments. Thus, new formulations for anti-parasitic drugs couldhelp to reposition them for new therapeutic indications, offering safer and more effectivetreatments by using a well-known drug